[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUP0204009A2 - 1. típusú nátrium-hidrogén csere (NHE-1) gátló kristályok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

1. típusú nátrium-hidrogén csere (NHE-1) gátló kristályok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0204009A2
HUP0204009A2 HU0204009A HUP0204009A HUP0204009A2 HU P0204009 A2 HUP0204009 A2 HU P0204009A2 HU 0204009 A HU0204009 A HU 0204009A HU P0204009 A HUP0204009 A HU P0204009A HU P0204009 A2 HUP0204009 A2 HU P0204009A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical compositions
compositions containing
sodium
crystals
preparation
Prior art date
Application number
HU0204009A
Other languages
English (en)
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0204009A2 publication Critical patent/HUP0204009A2/hu
Publication of HUP0204009A3 publication Critical patent/HUP0204009A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Water By Ion Exchange (AREA)

Abstract

A találmány (I) képletű NHE-1 gátló kristályokkal, az ilyen NHE-1gátló kristályokat alkalmazó eljárásokkal és az ilyen NHE-1 gátlókristályokat tartalmazó gyógyászati kompozíciókkal foglalkozik. AzNHE-1 gátló kristályok alkalmasak a szöveti iszkémiából eredőszövetkárosodások csökkentésére. A találmány kiterjed a kristályokelőállítására is. Ó
HU0204009A 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals, process for their preparation, pharmaceutical compositions containing them and their use HUP0204009A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (2)

Publication Number Publication Date
HUP0204009A2 true HUP0204009A2 (hu) 2003-03-28
HUP0204009A3 HUP0204009A3 (en) 2004-07-28

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204009A HUP0204009A3 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals, process for their preparation, pharmaceutical compositions containing them and their use

Country Status (44)

Country Link
EP (1) EP1224179B1 (hu)
JP (1) JP2003512455A (hu)
KR (1) KR100464526B1 (hu)
CN (2) CN1636991A (hu)
AP (1) AP2002002493A0 (hu)
AR (1) AR029402A1 (hu)
AT (1) ATE271047T1 (hu)
AU (1) AU778573B2 (hu)
BG (1) BG106729A (hu)
BR (1) BR0015275A (hu)
CA (1) CA2389020A1 (hu)
CO (1) CO5271714A1 (hu)
CZ (1) CZ20021332A3 (hu)
DE (1) DE60012208T2 (hu)
DK (1) DK1224179T3 (hu)
DZ (1) DZ3463A1 (hu)
EA (1) EA004937B1 (hu)
EE (1) EE200200227A (hu)
ES (1) ES2222923T3 (hu)
GE (1) GEP20043222B (hu)
GT (1) GT200000180A (hu)
HK (1) HK1048472B (hu)
HR (1) HRP20020366B1 (hu)
HU (1) HUP0204009A3 (hu)
IL (1) IL148581A0 (hu)
IS (1) IS6302A (hu)
MA (1) MA26840A1 (hu)
MX (1) MXPA02004358A (hu)
NO (1) NO20021821L (hu)
NZ (1) NZ517738A (hu)
OA (1) OA12080A (hu)
PA (1) PA8505501A1 (hu)
PE (1) PE20010764A1 (hu)
PL (1) PL354869A1 (hu)
PT (1) PT1224179E (hu)
SI (1) SI1224179T1 (hu)
SK (1) SK5312002A3 (hu)
SV (1) SV2002000209A (hu)
TN (1) TNSN00210A1 (hu)
TR (1) TR200201167T2 (hu)
UA (1) UA72002C2 (hu)
WO (1) WO2001030759A2 (hu)
YU (1) YU31502A (hu)
ZA (1) ZA200203295B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
YU51903A (sh) * 2001-01-31 2006-05-25 Pfizer Products Inc. Enolati inhibitora izmene natrijum-vodonik tipa-1
BR0307195A (pt) * 2002-01-30 2004-11-03 Pfizer Prod Inc Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide
AU2003219421A1 (en) * 2002-05-02 2003-11-17 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030078886A (ko) * 1998-02-27 2003-10-08 화이자 프로덕츠 인크. 허혈 치료용 ｎ-[(치환된 5원 트리아자 이불포화고리)카르보닐] 구아니딘 유도체

Also Published As

Publication number Publication date
TR200201167T2 (tr) 2002-08-21
CA2389020A1 (en) 2001-05-03
PA8505501A1 (es) 2003-09-05
EP1224179A2 (en) 2002-07-24
HK1048472B (zh) 2005-09-16
HUP0204009A3 (en) 2004-07-28
ES2222923T3 (es) 2005-02-16
BG106729A (bg) 2002-12-29
NZ517738A (en) 2005-06-24
WO2001030759A2 (en) 2001-05-03
EP1224179B1 (en) 2004-07-14
DZ3463A1 (fr) 2001-05-03
PL354869A1 (en) 2004-03-08
GT200000180A (es) 2002-04-11
MA26840A1 (fr) 2004-12-20
CZ20021332A3 (cs) 2002-10-16
CN1205205C (zh) 2005-06-08
CO5271714A1 (es) 2003-04-30
AU778573B2 (en) 2004-12-09
IS6302A (is) 2002-03-15
CN1384829A (zh) 2002-12-11
JP2003512455A (ja) 2003-04-02
HRP20020366A2 (en) 2004-02-29
AR029402A1 (es) 2003-06-25
GEP20043222B (en) 2004-04-26
HRP20020366B1 (en) 2005-04-30
SV2002000209A (es) 2002-07-16
KR100464526B1 (ko) 2005-01-03
AP2002002493A0 (en) 2002-06-30
HK1048472A1 (en) 2003-04-04
EE200200227A (et) 2003-06-16
ZA200203295B (en) 2003-06-25
UA72002C2 (en) 2005-01-17
NO20021821D0 (no) 2002-04-18
TNSN00210A1 (fr) 2005-11-10
YU31502A (sh) 2004-12-31
MXPA02004358A (es) 2002-11-07
PE20010764A1 (es) 2001-07-23
WO2001030759A3 (en) 2001-09-13
CN1636991A (zh) 2005-07-13
EA004937B1 (ru) 2004-10-28
DK1224179T3 (da) 2004-10-25
SI1224179T1 (en) 2004-10-31
SK5312002A3 (en) 2003-01-09
BR0015275A (pt) 2002-07-16
ATE271047T1 (de) 2004-07-15
AU7441500A (en) 2001-05-08
IL148581A0 (en) 2002-09-12
OA12080A (en) 2003-08-25
DE60012208D1 (de) 2004-08-19
DE60012208T2 (de) 2005-07-21
NO20021821L (no) 2002-04-18
KR20020040918A (ko) 2002-05-30
EA200200416A1 (ru) 2002-10-31
PT1224179E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
NO992821L (no) Ketobenzamider som calpain-inhibitorer
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
DE69705829D1 (de) Meta-substituierte phenylsulphonamidderivate
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
DK0889875T3 (da) Cycloproylalkansyrederivater
HUP0200580A2 (hu) Celecoxib polimorf kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
NO930143D0 (no) Piperidinforbindelser, deres fremstilling og bruk
SE9000871D0 (sv) Derivatives of thieno-triazolo-diazepine, a preparation process of the same and therapeutic compositions containing them
DK1404642T3 (da) Fremgangsmåde til fremstillimg af 7-amino-syn-3,5-dihydroxyheptansyrederivater, mellemprodukter derfor og fremgangsmåder til deres fremstilling
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
HUP0204009A2 (hu) 1. típusú nátrium-hidrogén csere (NHE-1) gátló kristályok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
SI1102765T1 (en) PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C)QUINOLIZIN-3-ONES DERIVATIVES
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
NO904135L (no) Fremgangsmaate for fremstilling av nye substituerte alkylpiperidiner og deres anvendelse som inhibitorer av kolesterolsyntese.
HUP0300651A2 (hu) Nátrium-hidrogén-cserélő 1-es típusú inhibitor (NHE-1) alkalmazása gyógyszerkészítmények előállítására és ezt tartalmazó gyógyszerkészítmények
NO962294L (no) Krystallinsk, polymorf form av (S,S,S)-N-(1-[2-karboksy-3-(N2-mesyllysylamino)propylÅ-1-cyklopentylkarbonyl)-tyrosin
HUP0203270A2 (hu) Hidroxánsav-származék mint a humán CD23 termelés inhibitora, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20061152L (no) Ny fremgangsmate for syntese av N-(S)-1-karboksybuty)-(S)-alanin og anvendelse derav for a syntetisere perindopril
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20001541L (no) Nye substituerte dimeriske forbindelser, fremgangsmÕte for deres fremstilling og farmasøytiske sammensetninger inneholdende dem
MXPA04004685A (es) Procedimientos para preparar inhibidores de tipo-1 de intercambiador sodio-hidrogeno.
DK1501823T3 (da) Hidtil ukendte piperidinyl-alkylamino-pyridazinon-derivater, en fremgangsmåde til fremstilling deraf og farmaceutiske præparater der indeholder forbindelserne
HUP0004187A2 (hu) Eljárás 1-es típusú nátrium-hidrogén-cserélő inhibitorként viselkedő guanidinszármazékok előállítására